Qiagen N.V. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 17 Posts
1 2
Thermo Fisher Acquires Qiagen For EUR 39 Per Share In Cash Or $11.5B
Article By: The Fly Tuesday, March 3, 2020 5:52 AM EST
Thermo Fisher Scientific and Qiagen announced that their boards have unanimously approved Thermo Fisher's proposal to acquire Qiagen for EUR 39 per share in cash.
In this article: TMO, QGEN
Read
Week In Review: Beigene Sets Record With $1.4 Billion Celgene Deal
Article By: ChinaBio® Today Saturday, July 8, 2017 2:35 PM EST
BeiGene of Beijing has entered a "transformational" collaboration with Celgene which involves BeiGene's clinical-stage PD-1 immuno-oncology drug, has a total value of almost $1.4 billion.
In this article: CELG, QGEN, BGNE, BYSI, ATNX
Read
Week In Review: Ping An Announces $1 Billion Fin-Tech/Healthcare VC Fund
Article By: ChinaBio® Today Saturday, May 6, 2017 5:13 PM EST
Ping An Insurance Group, China's largest insurer by market value, announced plans to launch a $1 billion international fund that will invest in fin-tech and healthcare startups. Ping An is already a player in the fin-tech area with Lufax.
In this article: SRNE, QGEN
Read
New Stocks On Most Attractive/Most Dangerous: January 2017
Article By: David Trainer Friday, January 13, 2017 10:20 AM EST
Our Most Attractive stocks have high and rising returns on invested capital and low price to economic book value ratios. Most Dangerous stocks have misleading earnings and long growth appreciation periods implied by their market valuations.
In this article: HAS, QGEN Also: VOXX, DLTR, FRAN, IDCC
Read
Illumina Misses Revenue Forecast Causing Collateral Damage To Biotechs
Article By: Rod Raynovich Tuesday, October 11, 2016 11:00 PM EST
Illumina shares crashed 25% to $139, after a warning on third quarter sales. The global leader in DNA sequencing systems warned that revenues missed forecast and would be $607M, well short of earlier guidance of $625-$630M.
In this article: TMO, RHHBY, IBB, ILMN, PACB, QGEN, XBI, XLV, FMI
Read
Biotech ETFs Lead Q3 Rally: XBI Breaks Out
Article By: Rod Raynovich Thursday, September 22, 2016 8:00 PM EST
The biotech sector is doing much better since BREXIT in late June despite a sell-off in late August. We are still trying to escape a bear market mentality because of the Q1 correction and concerns about drug prices.
In this article: AGN, JNJ, MDT, CPHD, ILMN, REGN, AMGN, BIIB, CELG, GILD, QGEN, XBI, XLV, Q, SRPT, BLUE, TSRO, IONS
Read
J.P.Morgan Healthcare Conference #1: Investors Move Into Life Science Stocks-Bouncing Off The Bottom
Article By: Rod Raynovich Tuesday, January 12, 2016 8:28 PM EST
We have a long way to recover in this bear market. The IBB​ touched near 52 week lows yesterday at $287 and is currently at $296 after a failed bounce then a recovery. We are down about 12% over five days.
In this article: ALR, JPM, NGS, TMO, RHHBY, CPHD, IBB, ILMN, ABAX, AFFX, QGEN
Read
Rayno Molecular Diagnostics And Tools Update: CPHD, HOLX, PACB
Article By: Rod Raynovich Wednesday, December 2, 2015 6:31 PM EST
Lackluster revenue growth has tempered stock gains since Q3 earnings reports however the sector has always had good investment potential due to M&A and new products. Stocks are up from October lows.
In this article: CPHD, ILMN, ABAX, HOLX, PACB, QGEN
Read
Biotech Rally Underway Trying To Overcome Gloomy Data
Article By: Rod Raynovich Saturday, November 14, 2015 11:14 AM EST
As of mid-morning trading the biotech and drug sector is one of the few winners yesterday. Energy has been the major drag on the market (crude down again yesterday) but materials are trying to bounce back yesterday with the XLB up over 1%.
In this article: ALR, VRX, ALNY, CRIS, ILMN, INCY, ISIS, SGEN, AMGN, CELG, CLVS, GILD, PACB, QGEN, VRTX, XLB, FCSC, NSTG, RXDX
Read
Rayno Tools And Molecular Diagnostics: Looking For Value
Article By: Rod Raynovich Thursday, November 5, 2015 7:30 PM EST
Life Science stocks took a big hit over the past summer and many have not fully recovered. The important metric to watch is sales growth because many of the smaller cap companies are still lagging in earnings growth so the PE tells you very little.
In this article: ALR, CPHD, GHDX, ILMN, LMNX, QDEL, ABAX, HOLX, NEOG, PACB, QGEN, FMI
Read
Week In Review: Xinbang Pharma Acquires Chinese Peptide Co. For $323 Million
Article By: ChinaBio® Today Saturday, May 9, 2015 3:54 PM EST
Bayer AG announced that the CFDA has approved Xarelto (rivaroxaban), a once-daily oral anticoagulant, for two new anti-clotting indications: strokes and deep vein thrombosis.
In this article: BAX, MACK, BAYN, CCM, QGEN, AZN, PVCT
Read
Rayno Portfolio Picks Up On Q1 Results: AMGN, ILMN
Article By: Rod Raynovich Wednesday, April 22, 2015 5:45 AM EST
Amgen stock was up 1.5 % yesterday, and over 2% after hours to $172. Total Q1 revenues were up 11% to $5B compared to prior quarter in 2014 and EPS increased by 33% to $2.48
In this article: AMGN, ILMN, ALXN, BIIB, GILD, REGN, RHHBY, ABAX, HOLX, QGEN, TMO, INCY, VRTX
Read
Rayno Life Science Portfolios: AMGN, CLVS, ILMN, RGEN, TMO
Article By: Rod Raynovich Tuesday, March 17, 2015 6:34 AM EST
The market roared back today with healthcare and biotech the strongest sectors.The Healthcare Select SPDR ETF was up 2.21% to $73.40. This is a 52 week high.
In this article: XBI, XLV, AMGN, REGN, ABBV, BIIB, FBT, SGEN, CPHD, ILMN, QGEN, SQNM, TMO
Read
Rayno Dx And Tools: 2015 Q1 Mid Quarter Update-FMI, CSII, HOLX, ALR
Article By: Rod Raynovich Thursday, February 19, 2015 4:41 PM EST
Major ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%.
In this article: FMI, CSII, HOLX, ALR, FBT, IBB, XBI, CPHD, ILMN, ABAX, QGEN, TMO, EXAS, GHDX, NEOG, NSTG, PACB, QDEL, SQNM, VRML
Read
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
Article By: ChinaBio® Today Sunday, February 15, 2015 10:44 AM EST
Deals, trials, financings and approvals in China healthcare sector this week.
In this article: CBMG, NEVPF, SHPHF, NVO, MRK, RPBIF, QGEN
Read
AstraZeneca And Qiagen Colaborate To Develop Diagnostic Test For Lung Cancer Patients
Article By: Dr. Hung Tran Wednesday, July 30, 2014 7:13 PM EST
AstraZeneca announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA.
In this article: AZN, QGEN
Read
1 to 16 of 17 Posts
1 2